AB13--Soleimanpour/Kauffman Univ of Pittsburgh mTDNA Research
Closed Special Notice Posted
- Solicitation number
- 36C25024Q0347
- Agency
-
Veterans Integrated Service Network 10
Veterans Health Administration, Department of Veterans Affairs
- Responses due
- Set-aside
- No set-aside
Opportunity facts
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of Veterans Affairs, VA Ann Arbor Medical Center VISN 10 published a Special Notice to award a sole source contract to the University of Pittsburgh. The notice involves providing expertise in the involvement of mitochondrial dysfunction in disease and aberrant mitochondrial DNA metabolism.
The Special Notice seeks to engage the University of Pittsburgh and subject matter expert Dr. Kaufman for technical support and services related to defective mitochondrial biogenesis and detection of mtDNA deletions. Interested parties have until February 29, 2024 to provide clear evidence that competition would be advantageous to the Government in order to contest the sole source determination. The period of performance is estimated to be from March 1, 2024 through February 28, 2025. No telephone inquiries will be accepted and responses must be emailed to the specified contracting officer by the stated deadline. The objective of the notice is to obtain specialized expertise and services related to mitochondrial research from the pre-determined source.
Notice text
The Department of Veterans Affairs, VA Ann Arbor Medical Center VISN 10,2215 Fuller Road, Ann Arbor MI 48105, in accordance with FAR 13.106-1(b), intends to award a contract request on a sole source basis with the University of Pittsburgh for the provision of expertise is the involvement of mitochondrial dysfunction in disease and how aberrant mitochondrial DNA (mtDNA) metabolism contributes to disease progression. NAICS 541715 and PSC code AB13 apply.
Dr. Kaufman is an Associate Professor in the Department of Medicine at the University of Pittsburgh. Dr. Kaufman s expertise is in the involvement of mitochondrial dysfunction in disease and how aberrant mitochondrial DNA (mtDNA) metabolism contributes to disease progression. Dr. Kaufman s long expertise in the study of mtDNA copy number control, mtDNA replication, and mtRNA transcription, specifically involving Tfam, serves a critical member of the research team to execute studies related to defective mitochondrial biogenesis in beta cells.
Detection of mtDNA deletions will be performed in the Kaufman Lab. Further, we will survey changes in mitochondrial antioxidant defense pathway by measuring expression of key antioxidant genes, including Prdx3, Txn2, Txnrd2, Ucp2, and Sod2, by qRT-PCR. As Director of the Mitochondrial Genetics Core for the Center for Metabolism and Mitochondrial Medicine, Dr. Kaufman also will be able to provide fee-for-service technical support for these assays on an as needed basis.
Period of performance is estimated as follows:
Base: March, 1st 2024 through February, 28th 2025
This notice of intent is not a request for competitive proposals. It is not a solicitation or request for offers. No solicitation package is available. A determination not to compete is solely within the discretion of the Government. Any response to this notice must show clear and convincing evidence that competition would be advantageous to the Government. Responses must be received no later than 4:00 pm EST on February 29th, 2024. No telephone inquiries will be accepted. All responses must be sent by email to kevin.adkins@va.gov
Files
| File | Type | Posted |
|---|---|---|
| 36C25024Q0347.docx | DOCX document |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity